All In Biotech

Drug Trial Radar · NCT06129851

Relugolix in Combination With Radiation Therapy for Treating Patients With High Risk Prostate Cancer

Quantifying Optimal Relugolix Duration With Radiation in High Risk Prostate Cancer (QURE-PC)

Last checked: Nov 20, 2026Latest source record: Nov 13, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

90

Planned (sponsor's estimate)

Start

Nov 20, 2023

Primary completion

Oct 23, 2025

Study completion Oct 23, 2026

Sponsor

Lead sponsor
University of Kansas Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Cancer Institute (NCI)
First posted
Nov 13, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II trial evaluates the best duration for relugolix to be given in combination with radiation therapy when treating patients with high risk prostate cancer. Prostate cancer is a hormonal influenced cancer. Part of the usual treatment for patients with prostate cancer is androgen deprivation therapy (ADT). ADT is used to lower the amount of testosterone in the body, because testosterone appears to help prostate cancer grow. Relugolix works to reduce testosterone levels, which may inhibit proliferation of prostate cancer cells. It is approved by the Food and Drug Administration to treat prostate cancer. Adding relugolix to standard radiation therapy might work better and have fewer side effects than prior forms of hormonal therapy, but the optimal duration of relugolix in combination with radiation is not known.

Conditions

  • Stage IIC Prostate Cancer AJCC v8
  • Stage III Prostate Cancer AJCC v8
  • Stage IV Prostate Cancer AJCC v8

Interventions

  • Biospecimen CollectionProcedure

    Undergo blood sample collection

  • Bone ScanProcedure

    Undergo bone scan

  • BrachytherapyRadiation

    Undergo brachytherapy

  • Computed TomographyProcedure

    Undergo CT

  • Dual X-ray AbsorptiometryProcedure

    Undergo DEXA scan

  • External Beam Radiation TherapyRadiation

    Undergo external beam radiation therapy

  • Magnetic Resonance ImagingProcedure

    Undergo MRI

  • PSMA PET ScanProcedure

    Undergo PSMA PET

  • Questionnaire AdministrationOther

    Ancillary studies

  • RelugolixDrug

    Given PO

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Biochemical recurrenceTime frame: Up to 3 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Kansas Cancer Center

    Kansas City, Kansas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.